Phase II/III Clinical Study Trends and Market Outlook

A recent study conducted by Industry Standard Research (ISR) surveyed 132 qualified decision-makers who are responsible for outsourced phase II/III drug development activities to gather their insights on current industry trends and what changes they expect over the next several years. Their responses provide a high-level view of the clinical development space to illustrate current market dynamics and inform strategic planning.

ISR’s research reveals key information on current and predicted study spend, findings on outsourced study proportions, and performance of providers’ trials by region that sponsors and service providers should be familiar with. Additionally, CROs can utilize this information to identify what trends are playing a role in selection, as well as gain understanding of who the key decision makers are within sponsor organizations.